Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
narlaprevir + ritonavir + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Narlaprevir (SCH 900518) is a potent small molecule inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 (NS3) serine protease. It is primarily metabolized by the cytochrome P450-3A4 system and can be pharmacokinetically boosted with ritonavir to enhance its plasma levels. Ritonavir acts as a CYP3A4 inhibitor to increase exposure of narlaprevir. Peginterferon alfa-2b is a pegylated form of interferon alpha that enhances immune response against HCV and prolongs drug activity in the body. The combination of these agents has been studied for the treatment of chronic hepatitis C infection (genotype 1), particularly in both treatment-naive and experienced patients. Clinical studies have shown that this triple regimen leads to rapid and significant reductions in HCV RNA levels[3][8]. Narlaprevir was developed by Schering-Plough.
- Brand names
- PegIntron RedipenPegIntron Redipen Pak
- Other names
- PEGINTRONPEG-IntronPEG-IFN-α-2b
02
Targets
CYP3A4 (Cytochrome P450 3A4)IFNAR (Immune system modulation via type I interferon receptor)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on narlaprevir + ritonavir + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on narlaprevir + ritonavir + peginterferon alfa-2b.